Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: theatrical (1), dramatic (4)

Carboplatin Paclitaxel EC Pembrolizumab Neoadjuvant Ver1.0

Description: Chemotherapy Protocol BREAST CANCER PEMBROLIZUMAB WITH CARBOPLATIN/PACLITAXEL AND EC NEOADJUVANT BREAST CANCER FOLLOWED BY ADJUVANT PEMBROLIZUMAB Regimen • Breast-Pembrolizumab with
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Carboplatin-Paclitaxel-EC-Pembrolizumab-Neoadjuvant.pdf

Papers-CoG-24.07.2024

Description: Date Time Location Chair Agenda Council of Governors 24/07/2024 14:00 - 16:00 Conference Room, Heartbeat/Microsoft Teams Jenni
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Governors/Papers-CoG-24.07.2024.pdf

Tracheostomy - patient information

Description: A tracheostomy is an opening created at the front of the neck allowing a tube to be inserted into the windpipe
Url: /Media/UHS-website-2019/Patientinformation/Childhealth/Tracheostomy-1139-patientinformation.pdf

Carboplatin-Pembrolizumab-Pemetrexed

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CARBOPLATIN (AUC 5)-PEMBROLIZUMAB-PEMETREXED Regimen • NSCLC – Carboplatin (AUC5)-Pembrolizumab-Pemetrexed Indication • Pembrolizumab
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Carboplatin-Pembrolizumab-Pemetrexed.pdf

UHS Inclusion and Belonging Strategy

Description: Our strategy sets out clear actions we will take to make UHS a place where every person feels they belong and
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/uhs-inclusion-and-belonging-strategy.pdf

Institutional information_2022-23_final

Description: Institutional information – key facts for inclusion as appropriate Support statements must be personal to your application to avoid the same document
Url: /Media/Southampton-Clinical-Research/Grants/Download/Institutional-information-2022-23-final.pdf

Papers Council of Governors 25 January 2023

Description: Agenda attachments 1 CoG Agenda - 25.01.2023.docx Date Time Location Chair Agenda Council of Governors 25/01/2023 14
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Papers-Council-of-Governors-25-Jan-2023.pdf

Cisplatin-Pembrolizumab-Pemetrexed

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CISPLATIN-PEMBROLIZUMAB-PEMETREXED Regimen • NSCLC – Cisplatin-Pembrolizumab-Pemetrexed Indication • Pembrolizumab in combination with
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Cisplatin-Pembrolizumab-Pemetrexed.pdf

Data protection and confidentiality policy

Description: University Hospitals Southampton NHS Foundation Trust needs to collect and use information about people with whom it deals in order to
Url: /Media/UHS-website-2019/Docs/Policies/Data-protection-and-confidentiality-policy.pdf

Institutional information_2021_final

Description: Institutional information – key facts for inclusion as appropriate Support statements must be personal to your application to avoid the same document
Url: /Media/Southampton-Clinical-Research/Grants/Download/Institutional-information-2021-final.pdf

351 to 360 of 368

Previous … 33 34 35 36 37 Next